検索結果
-
Takeda to Present Oncology Portfolio and Pipeline Data at the 2024 ASCO Annual Meeting POSTER PRESENTATION Developmental Therapeutics— Immunotherapy Saturday, June 1, 2024 9:00 AM–12:00 PM CDT Location: Hall A Updated results from first-in-human Phase 1 doseescalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors ーーーーーーーーーーーーーー Koji Tamadaも行くみたいですが、接待旅行でしょうね
-
連休がやっと終わった😄 M1が動き始めた様じゃのう😺 (必要な方は翻訳機能でも使ってくだされ) SAN DIEGO, May 8, 2024 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX), today announced the initiation of its Phase 1 first-in-human clinical study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of investigational compound NBI-1117567 in healthy adult participants. NBI-1117567 is an investigational, oral, M1/M4 (M1 preferring) selective muscarinic agonist for the potential treatment of neurological and neuropsychiatric conditions. "Neurocrine Biosciences has the largest muscarinic portfolio in the industry, with compounds in development for psychiatric and neurological disorders," said Eiry W. Roberts, M.D., Chief Medical Officer at Neurocrine Biosciences. "As an M1 preferring M1/M4 agonist, NBI-1117567 has the potential to treat symptoms of cognition in patients with neurological and neuropsychiatric conditions where psychosis might also be present."
-
Patients treated with uproleselan had a median overall survival of 13 months, compared to 12.3 months in the placebo arm. https://finance.yahoo.com/news/glycomimetics-announces-results-pivotal-phase-100000750.html ほんとだー。
-
UproleselanのP3試験(r/r AML)(進行中) NCT03616470(388症例) NCT05054543(140症例)(Chinese patients) ElacytarabineのP3試験(r/r AML) (NCT01147939、Clin Oncol. 2014;32:1919-26.) 計381症例(Primary end point:OS) Elacytarabine (n = 191) vs. Investigator choice control (n = 190) OS: 3.5 months (95% CI 2.8 to 4.8) vs. 3.3 months (95% CI 2.9 to 4.4) CR: 23% vs. 21% CRi: 15% vs. 12% Mean Age: 59 vs. 60 No. of previous regimens‖ 1: 9% vs. 9% 2: 61% vs. 67% >=3: 30% vs. 24% VosaroxinのP3試験(first r/r AML) (NCT01191801、Lancet Oncol. 2015;16:1025-1036.) 計711症例(Primary end point:OS) Vosaroxin plus cytarabine (n = 356) vs. cytarabine (n = 355) Median OS: 7.5 (95% CI 6.4-8.5) vs. 6.1 (95% CI 5.2-7.1) (Hazard ratio 0.87, 95% CI 0.73-1.02, Unstratified log-rank p=0.061; stratified p=0.024) CR: 30% vs. 16%, p<0.0001 CR/CRp/CRi: 37% vs. 19% mAge: 64 vs. 63 No. of previous induction cycles 1: 274 vs. 259 2: 82 vs. 95 >2: 0 vs.
-
🇺🇦ウクライナ:ストリッパーは免除 | HIV / がん患者と妊婦はスーツを着よう! ゼレンスキー大統領は、精神障害者、HIV感染者、癌患者、妊婦を前線への強制徴兵の対象とする新たな動員法案に署名した。 同時に、ウクライナの裁判官はストリッパーは兵役を免除され、通常の仕事を続ける必要がある「不可欠な労働者」であると判決を下した。 出典:ウクライナ政府 🇺🇦UKRAINE: STRIPPERS EXEMPT | HIV / CANCER PATIENTS AND PREGNANT WOMEN SUIT UP! Zelensky has signed a new mobilization bill into law that will have the mentally ill, the HIV-afflicted, cancer patients, and pregnant women be subject to mandatory draft for the front lines. At the same time, Ukrainian Judges ruled strippers were exempt from military service and called them 'essential workers' who needed to remain in their ordinary jobs. Source: Ukraine Gov
-
当社代表取締役会長である相良 暁は、次のように述べています。「今回Deciphera社の買収は、当社の目指すオンコロジー領域のポートフォリオ拡充のみならず、当社の欧米での事業展開を加速、また、キナーゼ創薬研究の強化にもつながるものと期待しています。Deciphera 社のミッション“Inspired by Patients : Defeat Cancer”は当社の企業理念 “病気と苦痛に対する人間の闘いのために”とも一致しています。今後はDeciphera社の独自性を尊重し、両社のさらなる成長につなげていきたいと考えています。」
-
https://youtu.be/y_aTLqPAtfI?si=jeWWf4vVakZhmbu4 Vasomune Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on the development of novel therapeutics for the treatment of diseases associated with vascular dysfunction, made an important announcement today that the first patient has been admitted in the Phase 2a clinical study. This study will be pivotal iin evaluating AV-001 in hospitalized patients experiencing severe symptoms COVID-19 disease. Vasomune Therapeutics, Inc.は、血管機能障害に関連する疾患の治療薬開発に特化した臨床段階のバイオ製薬会社であり、本日、臨床第2a相試験において最初の患者が入院したことを発表しました。本試験は、重篤な COVID-19 疾患の入院患者を対象に AV-001 を評価する極めて重要な試験となります。
Re:Re:Re:r/r AMLの二次治療での2&amp;hellip;
2024/05/18 20:16
CR判明してるから、もうやってると思うんよな。 これみたいに。 An initial planned interim analysis was conducted after 125 patients were evaluable for a response. The IDMC recommended continuing the study without change but requested another interim analysis when 200 patients were evaluable.